Genzyme Corp Drug Patent Portfolio

Genzyme Corp owns 2 orange book drugs protected by 11 US patents Given below is the list of Genzyme Corp's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10888544 Methods for treating Gaucher disease 13 Dec, 2038
Active
US10888547 Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase 31 Jan, 2031
Active
US11458119 Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase 24 Nov, 2030
Active
US8067427 Pharmaceutical compositions comprising ZD6474 08 Aug, 2028
Active
US7196205 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors 26 Jun, 2026
Active
US6916802 Amino ceramide-like compounds and therapeutic methods of use 29 Apr, 2022 Expired
US7253185 Amino ceramide-like compounds and therapeutic methods of use 29 Apr, 2022 Expired
US7615573 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors 29 Apr, 2022 Expired
US8642608 Quinazoline derivatives as VEGF inhibitors 06 Feb, 2022 Expired
US7173038 Quinazoline derivatives as VEGF inhibitors 14 Aug, 2021 Expired
USRE42353 Quinazoline derivatives and pharmaceutical compositions containing them 23 Sep, 2017 Expired


Given below is the list of recent legal activities going on the following drug patents of Genzyme Corp.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 26 Jun, 2024 US10888547
Payment of Maintenance Fee, 4th Year, Large Entity 26 Jun, 2024 US10888544
Payment of Maintenance Fee, 12th Year, Large Entity 17 May, 2023 US8067427
Recordation of Patent Grant Mailed 04 Oct, 2022 US11458119
Patent Issue Date Used in PTA Calculation 04 Oct, 2022 US11458119
Email Notification 15 Sep, 2022 US11458119
Issue Notification Mailed 14 Sep, 2022 US11458119
Email Notification 29 Jul, 2022 US11458119
Mailing Corrected Notice of Allowability 29 Jul, 2022 US11458119
Dispatch to FDC 28 Jul, 2022 US11458119
Application Is Considered Ready for Issue 28 Jul, 2022 US11458119
Corrected Notice of Allowability 26 Jul, 2022 US11458119
Information Disclosure Statement considered 26 Jul, 2022 US11458119
Pubs Case Remand to TC 15 Jul, 2022 US11458119
Issue Fee Payment Verified 14 Jul, 2022 US11458119


Genzyme Corp's Drug Patent Litigations

Genzyme Corp's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 05, 2019, against patent number US10888547. The petitioner , challenged the validity of this patent, with Genzyme Corporation as the respondent. Click below to track the latest information on how companies are challenging Genzyme Corp's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11458119 November, 2020 Decision
(27 Sep, 2021)
Hanlan Liu et al.
US10888547 April, 2019 Decision
(30 Apr, 2020)
Genzyme Corporation


Genzyme Corp Drug Patents' Oppositions Filed in EPO

Genzyme Corp drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 27, 2015, by Sandoz Ag. This opposition was filed on patent number EP10785289A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP16175117A May, 2020 Accord Healthcare Ltd Granted and Under Opposition
EP16175117A May, 2020 Hetero Labs Limited Granted and Under Opposition
EP16175117A May, 2020 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP10785289A Feb, 2015 SANDOZ AG Patent maintained as amended


Genzyme Corp's Family Patents

Genzyme Corp drugs have patent protection in a total of 56 countries. It's US patent count contributes only to 18.8% of its total global patent coverage. 13 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Genzyme Corp Drug List

Given below is the complete list of Genzyme Corp's drugs and the patents protecting them.


1. Caprelsa

Caprelsa is protected by 4 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8067427 Pharmaceutical compositions comprising ZD6474 08 Aug, 2028
(3 years from now)
Active
US8642608 Quinazoline derivatives as VEGF inhibitors 06 Feb, 2022
(2 years ago)
Expired
US7173038 Quinazoline derivatives as VEGF inhibitors 14 Aug, 2021
(3 years ago)
Expired
USRE42353 Quinazoline derivatives and pharmaceutical compositions containing them 23 Sep, 2017
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Caprelsa's drug page


2. Cerdelga

Cerdelga is protected by 7 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10888544 Methods for treating Gaucher disease 13 Dec, 2038
(14 years from now)
Active
US10888547 Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase 31 Jan, 2031
(6 years from now)
Active
US11458119 Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase 24 Nov, 2030
(6 years from now)
Active
US7196205 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors 26 Jun, 2026
(1 year, 8 months from now)
Active
US6916802 Amino ceramide-like compounds and therapeutic methods of use 29 Apr, 2022
(2 years ago)
Expired
US7253185 Amino ceramide-like compounds and therapeutic methods of use 29 Apr, 2022
(2 years ago)
Expired
US7615573 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors 29 Apr, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cerdelga's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Genzyme Corp News

Genzyme Files Lawsuit Against Sarepta Over Alleged Violation of Gene Therapy Patents

16 Aug, 2024

See More